Clinical Trial Update: Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anti-thymocyte globulin plus melphalan in relapsed multiple myeloma was terminated. Results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Alkeran (melphalan)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Mayo Clinic | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: TERMINATED | Results posted: 2010-10-18